Navigation Links
Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
Date:3/28/2011

SAN DIEGO, March 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA).  

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster Presentation Information:Title:

Rates of Recurrence and Mortality among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey DatabasesPresenter:

Erik R. Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MODate:

Saturday, April 2, 2011 Time:

1:00 p.m. to 2:15 p.m. Central TimeLocation:

Hilton Anatole Hotel, Trinity Ballroom, Dallas, TexasPresentation #:

152About OptimerOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
2. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
8. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Optimer Pharmaceuticals Announces Key Additions to Management Team
11. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... 07, 2018 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Creator and says the proof is undeniable. , Yisrayl scolds mainstream religions for allowing and ... Name. Yisrayl shows there is great meaning in the Name, and to take that away, ...
(Date:9/1/2018)... (PRWEB) , ... August 31, 2018 , ... Precision ... to their practice with offices in Irving and Southlake. Fellowship trained in Spine ... Pak, Dr. Byung Lee, Dr. John Milani, Dr. Jaytinder Sandhu, and Dr. Tariq Hendawi ...
(Date:9/1/2018)... ... September 01, 2018 , ... Dr. Payam Bostani is ... and orthodontic treatment he has been offering patients for twenty years at his Burbank ... dental services they are likely to need under a single roof. Periodontics is a ...
Breaking Medicine Technology:
(Date:8/31/2018)... GRAND RAPIDS, Mich. (PRWEB) , ... August 31, ... ... Services treatment provider, will host an Open House on Wednesday, September 12 from ... recovery options available in Grand Rapids, as well as tour the facility, meet ...
(Date:8/31/2018)... HUNTINGDON VALLEY, Pa. (PRWEB) , ... August 31, ... ... equal to those offered by the American Heart Association (AHA) to be responsive ... non-AHA business concerns and purchasing managers may now reap the benefits. Companies like ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... Jersey Gastroenterology for another year. Dr. Savon has been active in gastrointestinal research ... in comprehensive care for all gastrointestinal diseases and disorders for the past 25 ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and ... in September 2017 with a mission to develop a first-in-class therapeutic targeting ...
(Date:8/29/2018)... , ... August 29, 2018 , ... ... to learn, socialize or communicate with others. Physically, it is not possible to ... deal with problems may be challenged. People with autism may need assistance in ...
Breaking Medicine News(10 mins):